Economics of chronic heart failure

被引:287
作者
Berry, C
Murdoch, DR
McMurray, JJV
机构
[1] Univ Glasgow, MRC, Glasgow G12 8QQ, Lanark, Scotland
[2] Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland
关键词
heart failure; economics; healthcare expenditure;
D O I
10.1016/S1388-9842(01)00123-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic heart failure (CHF) is now recognized as a major and escalating public health problem. The costs of this syndrome, both in economic and personal terms, are considerable. The prevalence of CHF is 1-2% and appears to be increasing, in part because of ageing of the population. Economic analyses of CHF should include both direct and indirect costs of care. Healthcare expenditure on CHF in developed countries consumes 1-2% of the total health care budget. The cost of hospitalization represents the greatest proportion of total expenditure. Optimization of drug therapy represents the most effective way of reducing costs. Recent economic analyses in the Netherlands and Sweden suggest the costs of care are rising. (C) 2001 European Society of Cardiology. All rights reserved.
引用
收藏
页码:283 / 291
页数:9
相关论文
共 86 条
[81]  
Szucs TD, 1997, SCHWEIZ MED WSCHR, V127, P1234
[82]  
van Hout B A, 1993, Pharmacoeconomics, V3, P387, DOI 10.2165/00019053-199303050-00006
[83]  
Ventura HO, 2000, J AM COLL CARDIOL, V35, p558A
[84]   ECONOMIC OUTCOMES OF WITHDRAWAL OF DIGOXIN THERAPY IN ADULT PATIENTS WITH STABLE CONGESTIVE-HEART-FAILURE [J].
WARD, RE ;
GHEORGHIADE, M ;
YOUNG, JB ;
URETSKY, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (01) :93-101
[85]  
YOUNG J B, 1992, Journal of the American College of Cardiology, V19, p259A